title: Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
abstract: Proton pump inhibitors (PPIs) are commonly used drugs for the treatment of gastric reflux. Recent retrospective cohorts and large database studies have raised concern that the use of PPIs is associated with increased cardiovascular (CV) risk. However, there is no prospective clinical study evaluating whether the use of PPIs directly causes CV harm. We conducted a controlled, open-label, cross-over pilot study among 21 adults aged 18 and older who are healthy (n=11) or have established clinical cardiovascular disease (n=10). Study subjects were assigned to receive a PPI (Prevacid; 30 mg) or a placebo pill once daily for 4 weeks. After a 2-week washout period, participants were crossed over to receive the alternate treatment for the ensuing 4 weeks. Subjects underwent evaluation of vascular function (by the EndoPAT technique) and had plasma levels of asymmetric dimethylarginine (ADMA, an endogenous inhibitor of endothelial function previously implicated in PPI-mediated risk) measured prior to and after each treatment interval. We observed a marginal inverse correlation between the EndoPAT score and plasma levels of ADMA (r = -0.364). Subjects experienced a greater worsening in plasma ADMA levels while on PPI than on placebo, and this trend was more pronounced amongst those subjects with a history of vascular disease. However, these trends did not reach statistical significance, and PPI use was also not associated with an impairment in flow-mediated vasodilation during the course of this study. In conclusion, in this open-label, cross-over pilot study conducted among healthy subjects and coronary disease patients, PPI use did not significantly influence vascular endothelial function. Larger, long-term and blinded trials are needed to mechanistically explain the correlation between PPI use and adverse clinical outcomes, which has recently been reported in retrospective cohort studies.
authors.affiliation: Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: Yohannes T
authors.initials: YT
authors.lastname: Ghebremariam
authors.affiliation: Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA.
authors.forename: John P
authors.initials: JP
authors.lastname: Cooke
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Fouzia
authors.initials: F
authors.lastname: Khan
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Rahul N
authors.initials: RN
authors.lastname: Thakker
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Chang
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Nigam H
authors.initials: NH
authors.lastname: Shah
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Kevin T
authors.initials: KT
authors.lastname: Nead
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA nleeper@stanford.edu.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Leeper
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002140:California; D003327:Coronary Disease / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D064747:Lansoprazole / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011237:Predictive Value of Tests; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D015203:Reproducibility of Results; D018570:Risk Assessment; D013997:Time Factors; D034941:Upper Extremity / Q000098:blood supply*; D014664:Vasodilation / Q000187:drug effects*; D055815:Young Adult
chemical_list: D015415:Biomarkers; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C018524:N,N-dimethylarginine; D001120:Arginine
keywords: asymmetric dimethylarginine; cardiovascular risk factors; dimethylarginine dimethylaminohydrolase; nitric oxide; proton pump inhibitors
references.citation: Circulation. 1998 Nov 3;98(18):1842-7
references.pmid: 9799202
references.citation: Gastroenterology. 1992 Sep;103(3):913-8
references.pmid: 1499942
references.citation: Aliment Pharmacol Ther. 2000 Aug;14(8):963-78
references.pmid: 10930890
references.citation: Atherosclerosis. 2006 Apr;185(2):271-7
references.pmid: 16055131
references.citation: Trends Pharmacol Sci. 2011 Apr;32(4):258-64
references.pmid: 21429600
references.citation: Circulation. 2009 Mar 31;119(12):1592-600
references.pmid: 19289633
references.citation: Circulation. 2004 Apr 20;109(15):1813-8
references.pmid: 15096461
references.citation: Int J Vasc Med. 2012;2012:904141
references.pmid: 22500237
references.citation: Can J Cardiol. 2009 Jun;25 Suppl A:15A-20A
references.pmid: 19521569
references.citation: P T. 2011 Jul;36(7):434-45
references.pmid: 21931475
references.citation: Circulation. 2013 Aug 20;128(8):845-53
references.pmid: 23825361
references.citation: JAMA. 2009 Mar 4;301(9):937-44
references.pmid: 19258584
references.citation: CMAJ. 2009 Mar 31;180(7):713-8
references.pmid: 19176635
references.citation: Prev Med. 2009 Dec;49(6):468-72
references.pmid: 19804795
references.citation: Circulation. 2014 Apr 1;129(13):e428
references.pmid: 24687654
references.citation: Gastroenterology. 2009 Jul;137(1):80-7, 87.e1
references.pmid: 19362552
references.citation: Int J Cardiol. 2011 Dec 1;153(2):135-40
references.pmid: 21794936
references.citation: Heart. 2005 Jul;91(7):864-6
references.pmid: 15958346
references.citation: BMJ. 2011;342:d2690
references.pmid: 21562004
references.citation: Gut. 2004 Jan;53(1):5-7
references.pmid: 14684566
references.citation: Vasc Med. 2010 Aug;15(4):267-74
references.pmid: 20484311
references.citation: Heart Vessels. 2010 Jan;25(1):19-26
references.pmid: 20091394
references.citation: J Am Coll Cardiol. 2008 Jan 22;51(3):256-60
references.pmid: 18206732
references.citation: Circulation. 1999 Mar 9;99(9):1141-6
references.pmid: 10069780
references.citation: J Clin Invest. 2011 Apr;121(4):1258-60
references.pmid: 21436578
references.citation: J Appl Physiol (1985). 2011 Jun;110(6):1582-91
references.pmid: 21454745
references.citation: Nephrology (Carlton). 2006 Oct;11(5):381-5
references.pmid: 17014549
references.citation: Atherosclerosis. 2006 Feb;184(2):383-8
references.pmid: 15939423
references.citation: Int J Cardiol. 2013 Aug 10;167(3):965-74
references.pmid: 22464478
references.citation: Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H996-H1004
references.pmid: 12181129
references.citation: Circulation. 2012 Feb 28;125(8):978-86
references.pmid: 22261200
references.citation: Circ Res. 2005 Sep 2;97(5):e53-9
references.pmid: 16100045
references.citation: Gut. 2000 Feb;46(2):144-6
references.pmid: 10644301
references.citation: Clin Chem Lab Med. 2004;42(12):1377-83
references.pmid: 15576299
references.citation: Lancet. 1992 Mar 7;339(8793):572-5
references.pmid: 1347093
references.citation: Drug Metab Dispos. 2004 Aug;32(8):821-7
references.pmid: 15258107
references.citation: Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2536-40
references.pmid: 16931791
references.citation: Ann Intern Med. 2010 Sep 21;153(6):378-86
references.pmid: 20855802
references.citation: Diabetes Care. 2009 Nov;32 Suppl 2:S314-21
references.pmid: 19875572